CCR4 expression is also suppressed in SS T cells and/or cell lines by other therapies with efficacy in CTCL, including the rexinoid bexarotene and histone deacetylase inhibitors (HDACi) romidepsin and suberoylanilide hydroxamic acid (SAHA/vorinostat) [87,88]. The gene discussed is CCR4; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.